Search for content, post, videos

New Norwegian centre for precision immunotherapy

The centre, called Precision Immunotherapy Alliance (PRIMA), is led by Johanna Olweus, Professor and Head of Department of Cancer Immunology at Oslo University Hospital and Karl-Johan Malmberg, Professor at the University of Oslo.

Nine new Centers of Excellence have been awarded 1.4 billion NOK by the Norwegian Research Council. One of the centers will focus on precision immunotherapy and has received 155 million NOK.

Seven research group leaders

The alliance consists of in total seven research group leaders from Oslo University Hospital and the University of Oslo, reports Sofia Lindén/Oslo Cancer Cluster.

“The tools and technologies that we will develop based on our in-house concepts provide unique opportunities for this, in particular because of the complementary expertise of the various center partners.”

“Our center aims to identify targets and immune receptors that enable precise and effective treatment of cancer with manageable side effects, but the goal is that the therapies that will be developed can be used for many patients. The tools and technologies that we will develop based on our in-house concepts provide unique opportunities for this, in particular because of the complementary expertise of the various center partners,” commented Olweus to Oslo Cancer Cluster.

The timing is perfect

“The timing to form a Centre of Excellence in precision immunotherapy is perfect. The possibilities to make breakthroughs in cancer immunotherapy research have never been bigger. The research group leaders that have joined forces in Precision Immunotherapy Alliance possess complementary expertise needed to address outstanding challenges in the field,” commented Malmberg.

Malmberg and Olweus stressed that the success of the centre relies upon collaboration with different institutions and hope Oslo University Hospital and the University of Oslo will support them and that they can have a good dialogue with medical authorities, such as the Norwegian Medicines Agency, reports Sofia Lindén/Oslo Cancer Cluster.

“Innovation can also spur a generation of new start-ups and collaboration with existing industry, resulting in more clinical trials being attracted to Norway.”

“The aim is that Norwegian patients will get access to new therapies in clinical trials very early, rather than having to wait for new therapies to come from abroad. Innovation can also spur a generation of new start-ups and collaboration with existing industry, resulting in more clinical trials being attracted to Norway. We also believe that this will allow for us to attract talented researchers and clinicians who want to work with cancer immunotherapy, from Norway and abroad,” said Olweus.

Photo: iStock

Advertisement